Abbott Laboratories [ABT] vs Dexcom [DXCM] Detailed Stock Comparison

Abbott Laboratories

NYSE
Loading...

Dexcom Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Abbott Laboratories wins in 12 metrics, Dexcom Inc. wins in 7 metrics, with 0 ties. Abbott Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Abbott Laboratories Dexcom Inc. Better
P/E Ratio (TTM) 25.97 30.03 Abbott Laboratories
Price-to-Book Ratio 3.09 8.63 Abbott Laboratories
Debt-to-Equity Ratio 26.79 50.85 Abbott Laboratories
PEG Ratio -1.41 0.39 Dexcom Inc.
EV/EBITDA 13.74 19.85 Abbott Laboratories
Profit Margin (TTM) 13.90% 17.94% Dexcom Inc.
Operating Margin (TTM) 16.50% 25.64% Dexcom Inc.
EBITDA Margin (TTM) 16.50% 25.64% Dexcom Inc.
Return on Equity 12.36% 34.50% Dexcom Inc.
Return on Assets (TTM) 7.52% 8.89% Dexcom Inc.
Free Cash Flow (TTM) $7.40B $1.08B Abbott Laboratories
Dividend Yield 1.97% N/A N/A
1-Year Return -34.98% -8.07% Dexcom Inc.
Price-to-Sales Ratio (TTM) 3.57 5.10 Abbott Laboratories
Enterprise Value $166.96B $23.09B Abbott Laboratories
EV/Revenue Ratio 3.70 4.95 Abbott Laboratories
Gross Profit Margin (TTM) N/A 62.93% N/A
Revenue per Share (TTM) $26 $12 Abbott Laboratories
Earnings per Share (Diluted) $3.57 $2.05 Abbott Laboratories
Beta (Stock Volatility) 0.78 1.56 Abbott Laboratories
Short % of Float 1.53% 4.93% Abbott Laboratories

Abbott Laboratories vs Dexcom Inc. Stock Performance Analysis

Loading Price Chart...

ABT
DXCM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Abbott Laboratories0.56%-2.02%4.97%-19.35%-30.98%-28.60%
Dexcom Inc.-1.53%-3.13%20.43%11.88%12.92%11.54%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Abbott Laboratories-34.98%-16.97%-20.08%135.84%255.56%329.52%
Dexcom Inc.-8.07%-42.07%-27.92%315.26%2,149.85%2,129.88%

Performance & Financial Health Analysis: Abbott Laboratories vs Dexcom Inc.

MetricABTDXCM
Market Information
Market Cap i$160.70B$23.76B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i13,495,5834,652,604
90 Day Avg. Volume i12,934,4614,100,848
Last Close$88.67$74.22
52 Week Range$81.97 - $139.06$54.11 - $89.98
% from 52W High-36.24%-17.52%
All-Time High$142.60 (Dec 27, 2021)$164.86 (Nov 15, 2021)
% from All-Time High-37.82%-54.98%
Growth Metrics
Quarterly Revenue Growth0.08%0.13%
Quarterly Earnings Growth-0.19%0.76%
Financial Health
Profit Margin (TTM) i0.14%0.18%
Operating Margin (TTM) i0.17%0.26%
Return on Equity (TTM) i0.12%0.35%
Debt to Equity (MRQ) i26.7950.85
Cash & Liquidity
Book Value per Share (MRQ)$30.02$7.14
Cash per Share (MRQ)$5.14$5.19
Operating Cash Flow (TTM) i$10.80B$1.44B
Levered Free Cash Flow (TTM) i$13.77B$719.54M
Dividends
Last 12-Month Dividend Yield i1.97%N/A
Last 12-Month Dividend i$2.40N/A

Valuation & Enterprise Metrics Analysis: Abbott Laboratories vs Dexcom Inc.

MetricABT (Apr 24, 2026)DXCM (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i25.9730.03
Forward P/E i15.2920.59
PEG Ratio i-1.410.39
Price to Sales (TTM) i3.575.10
Price to Book (MRQ) i3.098.63
Market Capitalization
Market Capitalization i$160.70B$23.76B
Enterprise Value i$166.96B$23.09B
Enterprise Value Metrics
Enterprise to Revenue i3.704.95
Enterprise to EBITDA i13.7419.85
Risk & Other Metrics
Beta i0.781.56
Book Value per Share (MRQ) i$30.02$7.14

Financial Statements Comparison: Abbott Laboratories vs Dexcom Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricABT (2025)DXCM (2025)
Revenue/Sales i44.33B4.66B
Cost of Goods Sold i19.32B1.86B
COGS % of Revenue i43.6%39.9%
Gross Profit i25.01B2.80B
Gross Margin i56.4%60.1%
Research & Development i2.94B599.10M
Operating Income (EBIT) i8.05B911.80M
Operating Margin i18.2%19.6%
EBITDA i12.03B1.36B
EBITDA Margin i27.1%29.1%
Pre-Tax Income i8.47B1.09B
Pre-Tax Income % of Revenue i19.1%23.3%
Income Tax i1.94B252.10M
Income Tax % of Revenue i4.4%5.4%
Net Income (Profit) i6.52B836.30M
Profit Margin i14.7%17.9%

Balance Sheet & Liquidity Metrics

MetricABT (2025)DXCM (2025)
Cash & Equivalents i8.52B917.70M
Total Current Assets i26.00B4.03B
Total Current Assets % of Revenue i58.6%86.5%
Total Current Liabilities i16.50B2.14B
Total Current Liabilities % of Revenue i37.2%46.0%
Long-Term Debt i10.83B1.37B
Long-Term Debt % of Revenue i24.4%29.3%
Total Shareholders Equity i52.77B2.75B
Retained Earnings i49.78B2.43B
Retained Earnings % of Revenue i112.3%52.2%
Property, Plant & Equipment i17.57B77.40M

Cash Flow Statement Comparison

MetricABT (2025)DXCM (2025)
Operating Cash Flow i10.80B1.48B
Operating Cash Flow % of Revenue i24.4%31.7%
Capital Expenditures i-2.17B-363.50M
Free Cash Flow i7.40B1.08B
FCF Margin i16.7%23.1%
Debt Repayment i-1.50B-1.21B
Common Stock Repurchase i-893.00M-500.00M

Short Interest & Institutional Ownership Analysis

MetricABTDXCM
Shares Short i23.83M14.72M
Short Ratio i1.933.77
Short % of Float i1.53%4.93%
Shares Outstanding i1.74B384.80M
Float Shares i1.73B382.94M
% Held by Insiders i0.54%0.28%
% Held by Institutions i82.23%101.50%
% Held by Public i17.23%-1.78%

Dividend Analysis & Yield Comparison: Abbott Laboratories vs Dexcom Inc.

MetricABTDXCM
Last 12-Month Dividend i$2.40N/A
Last 12-Month Dividend Yield i1.97%N/A
3-Year Avg Annual Dividend i$2.24N/A
3-Year Avg Dividend Yield i0.50%N/A
3-Year Total Dividends i$6.72N/A
Ex-Dividend DateJan 15, 2026N/A